Full archive
Pharmacogenomics
Week of 30 June 2026
11 articles
Geno'X Veille — genox-veille.fr
Key takeaways this week
- ►CYP2C19 and voriconazole — inflammation (CRP) phenoconverts metabolism: genotype alone insufficient, TDM coupled with CRP recommended.
- ►HLA-B and anticonvulsants — UK CERSI-PGx guideline: HLA genotyping for all before carbamazepine, regardless of ancestry.
- ►CYP2C19 and dual antiplatelet therapy — 17-fold infarction risk in East Asian populations: Western guidelines do not transpose.
- ►CYP2C19 and escitalopram — quantitative comedication phenoconversion model on 2,852 real-world patients.
- ►CYP2C19 at point of care — rapid CRISPR assay, ≥ 97% concordance with Sanger for clopidogrel.
Category:
Filters··Min. score
11 articles of 11
Sort
CYP2C19
PubMed★ Top pick
Inflammation-driven variability in drug metabolism: Insights from voriconazole treatment of HSCT recipients
Voriconazole after hematopoietic stem cell transplantation — inflammation-driven phenoconversion
0
PhenoconversionAdverse reaction
Br J Clin Pharmacol 2026· MarRead
HLA-B
PubMed★ Top pick
HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx)
Hypersensitivity to carbamazepine, oxcarbazepine and eslicarbazepine — *HLA* genotyping
0
New recommendationAdverse reaction
Br J Clin Pharmacol 2026· AprRead
CYP2C19
PubMed★ Top pick
Paradoxical myocardial infarction risk with dual antiplatelet therapy in East Asian ischaemic stroke: a nationwide real-world cohort study and pharmacogenomic risk prediction model
Secondary ischemic stroke prevention — dual antiplatelet therapy and *CYP2C19* in East Asian populations
0
CardiologyAdverse reactionRecurrent variant
Ther Adv Neurol Disord 2026· JunRead
CYP2C19
medRxiv★ Top pick
Pharmacogenetic phenoconversion modeling of drug-drug-gene interactions on CYP2C19 activity: effects of comedication by genotype on escitalopram concentrations
Escitalopram — modeling of drug-drug-gene interactions on *CYP2C19* activity
0
PhenoconversionNew interaction
medRxiv 2026· JunRead
CYP2C19
PubMedCRISPR-Based Assay for Point-of-Care Pharmacogenetic CYP2C19 Genotyping
Point-of-care *CYP2C19* genotyping — CRISPR assay
0
CardiologyPreemptive genotypingNew tool
ACS Sens 2026· JunRead
TPMT
PubMedThe decline of 6-thioguanine nucleotides is not linked to impaired efficacy or safety of thiopurines in pregnant women with inflammatory bowel disease
Thiopurines during pregnancy — inflammatory bowel disease
0
ImmunosuppressantsDose recommendationAdverse reaction
Br J Clin Pharmacol 2026· MarRead
CYP2D6
PubMedPredicting Social Cognitive Outcomes in Adolescent-Onset Schizophrenia: A Hierarchical Analysis of Pharmacogenetic, Clinical, and Environmental Factors
Adolescent-onset schizophrenia — social cognition and *CYP2D6* metabolism
0
PsychiatryPhenoconversionRecurrent variant
J Clin Med 2026· JunRead
Adverse drug reactions — burden of metabolic pathway inhibition
PubMedThe quantitative impact of metabolism-inhibiting drugs on the occurrence of adverse drug reactions — A backward selection approach
Adverse drug reactions — burden of metabolic pathway inhibition
0
Adverse reactionPhenoconversion
Br J Clin Pharmacol 2026· FebRead
CYP2C19
PubMedA primary care pharmacogenetic precision medicine pilot based on specific Māori tribal ethical frameworks and principles
Primary care pharmacogenetics — Māori tribal ethical framework
0
Preemptive genotypingRecurrent variant
J Community Genet 2026· JunRead
HLA-B
PubMedSystematic review on genetic polymorphisms associated with idiosyncratic drug-induced liver injury (iDILI): iDILInet as an interactive visualization tool
Idiosyncratic drug-induced liver injury (iDILI) — genetic susceptibility
0
Adverse reactionNew tool
Acta Pharm Sin B 2026· MarRead
CYP2B6
PubMedClinical Relevance of the 516 G>T Polymorphism in CYP2B6 and Its Effects on Efavirenz Concentrations in Patients with HIV and Tuberculosis: A Meta-analysis
Efavirenz in HIV/tuberculosis patients — *CYP2B6* 516 G>T polymorphism
0
Recurrent variantAdverse reaction
Eur J Drug Metab Pharmacokinet 2026· JunRead
References and sources
- CYP2C19 — Voriconazole after hematopoietic stem cell transplantation — inflammation-driven phenoconversion. Br J Clin Pharmacol 2026. PMID 41766069. Score 10/10. https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/bcp.70501?af=R
- HLA-B — Hypersensitivity to carbamazepine, oxcarbazepine and eslicarbazepine — *HLA* genotyping. Br J Clin Pharmacol 2026. PMID 42002301. Score 9/10. https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/bcp.70559?af=R
- CYP2C19 — Secondary ischemic stroke prevention — dual antiplatelet therapy and *CYP2C19* in East Asian populations. Ther Adv Neurol Disord 2026. PMID 42368890. Score 9/10. https://pubmed.ncbi.nlm.nih.gov/42368890/
- CYP2C19 — Escitalopram — modeling of drug-drug-gene interactions on *CYP2C19* activity. medRxiv 2026. doi:10.64898/2026.06.23.26356327. Score 9/10. https://www.medrxiv.org/content/10.64898/2026.06.23.26356327v1
- CYP2C19 — Point-of-care *CYP2C19* genotyping — CRISPR assay. ACS Sens 2026. PMID 42345496. Score 8/10. https://pubmed.ncbi.nlm.nih.gov/42345496/
- TPMT — Thiopurines during pregnancy — inflammatory bowel disease. Br J Clin Pharmacol 2026. PMID 41846507. Score 7/10. https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/bcp.70520?af=R
- CYP2D6 — Adolescent-onset schizophrenia — social cognition and *CYP2D6* metabolism. J Clin Med 2026. PMID 42355642. Score 7/10. https://pubmed.ncbi.nlm.nih.gov/42355642/
- Adverse drug reactions — burden of metabolic pathway inhibition. Br J Clin Pharmacol 2026. PMID 41721490. Score 6/10. https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/bcp.70494?af=R
- CYP2C19 — Primary care pharmacogenetics — Māori tribal ethical framework. J Community Genet 2026. PMID 42365224. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42365224/
- HLA-B — Idiosyncratic drug-induced liver injury (iDILI) — genetic susceptibility. Acta Pharm Sin B 2026. PMID 42368566. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42368566/
- CYP2B6 — Efavirenz in HIV/tuberculosis patients — *CYP2B6* 516 G>T polymorphism. Eur J Drug Metab Pharmacokinet 2026. PMID 42337190. Score 5/10. https://pubmed.ncbi.nlm.nih.gov/42337190/